Physician profile
David W Harding
NPI 1457576043
$15,348.52
in general payments reported to CMS, 2019-2025
42 companies · $3,234 in 2025
The $3,234 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,368 · 2020: $740 · 2021: $1,610 · 2022: $4,158 · 2023: $1,927 · 2024: $2,311 · 2025: $3,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,104 · Travel and Lodging: $1,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,103.88 |
| Travel and Lodging | $1,368.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,734.87 | 2019-2025 | Ultreon, Optis, Dragonfly Opstar |
| Abiomed | $2,325.61 | 2019-2025 | Impella |
| Heartflow, INC. | $1,980.86 | 2019-2025 | Ffrct |
| Amgen INC. | $1,364.06 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $830.74 | 2019-2025 | |
| Shockwave Medical, INC | $786.11 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $724.08 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $689.41 | 2019-2025 | Wainua, Farxiga |
| Pfizer INC. | $388.72 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.54 | 2019-2024 | Jardiance |
| Penumbra, INC. | $300.47 | 2019-2022 | |
| Medtronic, INC. | $283.94 | 2021-2025 | Onyx Frontier, Biomedicus |
| Janssen Pharmaceuticals, INC | $269.92 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $201.33 | 2021-2024 | Nexletol, Nexlizet |
| Sanofi-Aventis U.S. LLC | $190.04 | 2019-2024 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $188.38 | 2019-2025 | Kengreal |
| Irhythm Technologies, INC. | $173.38 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| Zoll Circulation INC | $146.56 | 2023 | Therox Ds2 Console, Downstream Cartridge, Catheter |
| Merck Sharp & Dohme LLC | $126.04 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $116.09 | 2023-2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $114.09 | 2019-2025 | Camzyos |
| Terumo Medical Corporation | $110.70 | 2023 | Metacross Otw, Heartrail, Glidewire |
| Teleflex LLC | $102.52 | 2022-2025 | Twin-Pass |
| Acist Medical Systems, INC. | $99.50 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.38 | 2022-2023 | |
| Cvrx, INC. | $73.17 | 2021-2023 | Barostim Neo System |
| Lundbeck LLC | $68.70 | 2019 | |
| Novo Nordisk INC | $63.86 | 2021-2024 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $62.27 | 2023-2024 | Opsumit, Uptravi |
| Cardiovascular Systems INC. | $55.85 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $49.66 | 2023-2025 | Onpattro |
| Scpharmaceuticals INC. | $44.49 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $43.38 | 2019 | |
| Gilead Sciences, INC. | $40.90 | 2019 | |
| Boston Scientific Corporation | $37.67 | 2024-2025 | Avvigo Guidance System, Synergy |
| Kiniksa Pharmaceuticals International, Plc | $31.58 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $23.40 | 2024 | Sapien 3 Ultra Resilia |
| Portola Pharmaceuticals, LLC | $23.34 | 2019 | |
| Daiichi Sankyo INC. | $18.94 | 2023 | Injectafer |
| Medtronic Vascular, INC. | $14.74 | 2019 | |
| Amarin Pharma, INC. | $14.30 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Harding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.